Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-774 in African American Patients With Advanced NSCLC
NCT00230126Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Oct 2005
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Oct 2005; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00230126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230126.